sandy macrae he is the ceo of sangamo therapeutics to learn more about his company. ney. >> good afternoon. >> okay, so sandy, just so you know, six years ago we had sangamo on the show, and kind of want to reintroduce your company because it's been a long journey. what have you been up to >> so sangamo is like two companies. as you say, we've been around for 25 years when we started, there wasn't even an ability to sequence the human genome and in that time, sangamo pioneered the first ever editing of human cells, the first ever editing in a human, and then i took over four years ago, and we're like a startup based on a new technology and the technology that is proven and trusted >> let's talk about the partnership that you really has transformation part that was announced last week. it seems to me that one kind of derisked the company, but two, kept as much as say $6 billion in upside if things work out how did you get such a magnificent deal >> it is a good deal it's a really good deal. and it's easy to talk economics. but for a company like us where we can change